Sanofi’s (SAN FP) Cenrifki recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Sanofi’s Cenrifki receiving a positive recommendation from the CHMP for EU approval is notable as it could significantly enhance their product pipeline in the growing multiple sclerosis market. This approval not only validates their research efforts but may also drive stock performance and investor sentiment, particularly in the pharmaceuticals sector, and could spark further M&A activity as competitors assess their own pipelines.